Table 3 Demographics comparison of the elderly and younger patients after PS matching
Variable | Aged < 70 years (n = 128) | Aged ≥ 70 years (n = 64) | P value | Standardized mean difference |
|---|---|---|---|---|
Age (years) | 57 (31–69) | 72.5 (70–83) | < 0.001 | |
Gender, male | 73 (57.0%) | 43 (67.2%) | 0.175 | 0.075 |
ASA | 0.200 | 0.083 | ||
I–II | 106 (82.8%) | 48 (75.0%) | ||
III | 22 (17.2%) | 16 (25.0%) | ||
Comorbidity | 65 (50.8%) | 41 (61.1%) | 0.081 | 0.086 |
Cerebrovascular disease | 4 (3.1%) | 2 (3.1%) | 1.000 | < 0.001 |
Arrhythmia | 3 (2.3%) | 1 (1.6%) | 1.000 | < 0.001 |
Ischemic heart disease | 11 (8.6%) | 6 (9.4%) | 0.857 | 0.076 |
Diabetes mellitus | 21 (16.4%) | 12 (18.8%) | 0.685 | 0.089 |
Hypertension | 49 (38.3%) | 31 (48.4%) | 0.178 | 0.077 |
Chronic obstructive pulmonary disease | 0 (0.0%) | 1 (1.6%) | 0.333 | 0.083 |
Chronic renal dysfunction | 0 (0.0%) | 1 (1.6%) | 0.333 | 0.065 |
Accompanying liver disease | 10 (7.8%) | 2 (3.1%) | 0.343 | 0.076 |
Primary tumor sideness | 0.447 | |||
Right side | 24 (18.8%) | 15 (23.4%) | ||
Left side | 104 (81.3%) | 49 (76.6%) | ||
Primary T | 0.557 | |||
pT1-T2 | 8 (6.3%) | 6 (9.4%) | ||
pT3-T4 | 120 (93.8%) | 58 (90.6%) | ||
Primary N | 0.653 | 0.035 | ||
pN0 | 36 (28.1%) | 20 (31.3%) | ||
pN1-2 | 92 (71.9%) | 44 (68.8%) | ||
Number of liver metastases(LM) | 0.433 | 0.056 | ||
≤ 3 | 106 (82.8%) | 50 (78.1%) | ||
> 3 | 22 (17.2%) | 14 (21.9%) | ||
Distribution of LM | 1.000 | |||
Unilobar | 80 (62.5%) | 40 (62.5%) | ||
Bilobar | 48 (37.5%) | 24 (37.5%) | ||
Maximum diameter of LM | 0.509 | |||
≤ 5 cm | 103(80.5%) | 54(84.4%) | ||
> 5 cm | 25(19.5%) | 10(15.6%) | ||
Temporal relationship | 0.126 | |||
Synchronous | 61 (47.7%) | 38 (59.4%) | ||
Metachronous | 67 (52.3%) | 26 (40.6%) | ||
Preoperative chemotherpy cycles | 1.000 | < 0.001 | ||
≤ 6 cycles | 122 (95.3%) | 61 (95.3%) | ||
> 6 cycles | 6 (4.7%) | 3 (4.7%) | ||
Preoperative clinical risk score (CRS) | 0.535 | 0.065 | ||
0–2 | 76 (59.4%) | 35 (54.7%) | ||
3–5 | 52 (40.6%) | 29 (45.3%) | ||
RAS/BRAF mutation | 47 (36.9%) | 22 (34.4%) | 0.750 | 0.046 |
Preoperative CEA (ng/ml) | 9.10 (0.93–794.50) | 9.41 (1.23–224.80) | 0.858 | 0.102 |
Preoperative CA199 (U/ml) | 28.11 (0.00–28,385.00) | 24.06 (0.00–1354.00) | 0.360 | |
Repeat resection after recurrence | 20 (15.6%) | 8 (12.5%) | 0.563 | 0.078 |
Postoperative chemotherapy | 86 (67.2%) | 38 (59.4%) | 0.286 | 0.094 |
Preoperative chemotherapy regimes | 0.063 | |||
Oxaliplatin-based | 37 (28.9%) | 29 (45.3%) | ||
Irinotecan-based | 8 (6.3%) | 5 (7.8%) | ||
5-Fu-based | 1 (0.8%) | 2 (3.1%) | ||
Hepatic artery infusion | 4 (3.1%) | 1 (1.6%) | ||
Postoperative chemotherapy regimes | 0.601 | |||
Oxaliplatin-based | 50 (39.1%) | 28 (43.8%) | ||
Irinotecan-based | 22 (17.2%) | 6 (9.4%) | ||
5-Fu-based | 8 (6.3%) | 3 (4.7%) | ||
Hepatic artery infusion | 1 (0.8%) | 0 (0%) | ||